

## **Suven Life Sciences presented several scientific posters at Neuroscience-2021 virtual conference held during 8-11, November 2021.**

Hyderabad, India (November 12, 2021): Suven Life Sciences Ltd (Suven) presenting several scientific posters at Neuroscience-2021, the annual meeting of Society for Neuroscience (SFN), USA, virtual conference held during 8-11, November 2021. These presentations representing the key results from preclinical to clinical data of portfolio of new chemical entities (NCEs) Suven developing through novel mechanism of action for various CNS indications: Agitation, Dementia / cognitive dysfunction associated with Alzheimer's and Parkinson's disease, Major Depressive Disorders, Schizophrenia and Psychotic disorders.

P239.02: Masupirdine (SUVN-502): A promising clinical candidate for the management of agitation in patients with dementia of Alzheimer's type.

P267.08: Usmarapride (SUVN-D4010): A 5-HT<sub>4</sub> receptor partial agonist alleviates haloperidol-induced Parkinson's disease associated cognitive dysfunction

P898.01: Ropanicant (SUVN-911): An orally active neuronal nicotinic acetylcholine  $\alpha 4\beta 2$  receptor antagonist for the management of depression

P408.04: SUVN-1301102: Preclinical pharmacokinetic and pharmacodynamic profiling of a P2X<sub>7</sub> receptor antagonist.

P717.01: Effect of 5-HT<sub>7R</sub> agonist and antagonist on biological markers and pathophysiological mechanisms in neuropathic rats.

P907.01: SUVN-5107002: A potent serotonin and weak dopamine modulator demonstrating antipsychotic effects with no motor side effects.

P715.01: SUVN-2300191, a 5-hydroxytryptamine 1a receptor partial agonist for the treatment of depressive disorders.

P715.05: SUVN-4404091, a multi-target compound for the treatment of schizophrenia and psychotic disorders

### *Disclaimer and Risk Statement:*

*Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com